Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin and Propranolol for Portal Hypertension in Cirrhosis
NCT01897051Phase 3Unknown
- Sponsor
- Yonsei University
- Start
- Jul 2013
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rifaximin in Portal Hypertension (PH) and esophageal varices (2 arms), sponsored by Yonsei University. Primary endpoint: Hepatic vein pressure gradient at 6 weeks. Status: unknown.
02
Drugs
rifaximin
03
Conditions
Portal Hypertension (PH)esophageal varices
Beyond the preview
Go deeper on NCT01897051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01897051.